Cost competitiveness is a major driving force in the semiconductor industry. The processing cost of an individual die is directly proportional to its size. Advances in processing technology have shrunk the device sizes in wire-bonded chips, resulting in a smaller die core size. However, the space below wire-bond pads remains relatively underutilized because of the reliability concern that electrical loads transmitted during bonding can cause failures in the underlying devices. Recently, studies have attempted to improve the use of space below wire-bond pads. Hence, the circuits under pads (CUP) structure modified layout rules to include circuits structure under pads, was developed, and extensive qualification work is required to meet reliability standards. The main purpose of this paper is to investigate the damage caused by the wirebonding process of CUP devices on the in-line assembly packaging manufacture. The root cause of wirebonding failures analyzed were based on the CUP structure and several wire bond parameters; such as bonding force, ultrasonic current, bonding time period, capillary type, machine, and wafer source, which were also confirmed with the DOE/JMP engineer technique. Finally, results were also used to implement the corrective action and the assembly yield of CUP Device has been improved, successfully.

The purpose of this study was to evaluate the stability of two preparations of vancomycin oral solution in two different storage containers, capped amber oral-dosing syringes and heat-sealed oral-dosing cups, stored under refrigerated conditions. Commercially available grape-flavored vancomycin oral preparation and compounded vancomycin for intravenous use in cherry syrup oral preparation were divided into 5-mL aliquots into heat-sealed plastic dosing cups and capped oral-dosing syringes. All samples were stored under refrigeration (2°C to 8°C) and evaluated at days 0, 3, 7, 14, 30, 60, and 90. For each evaluation, samples were visually inspected and analyzed for potency using a stability-indicating high-performance liquid chromatographic method with ultraviolet detection. Over the study period, at least 90% of the initial concentrations for the preparation and the product in both storage containers were retained at 60 days. The commercially available oral vancomycin further demonstrated stability within 90% out to 90 days in the syringe and the unit-dose cups. Visual inspection revealed no changes in the grape-flavored vancomycin oral preparation, but a detectable red-dye precipitate could be seen in the crevices of the dosing cups from the vancomycin in cherry syrup oral preparation after 60 days. Commercially available grape-flavored vancomycin oral preparation was stable up to 90 days, and com- pounded vancomycin for intravenous use in cherry syrup oral preparation maintained stability for 60 days when dispensed in capped amber polypropylene oral-dosing syringes and heat-sealed plastic dosing cups when stored at refrigerated conditions.